Alzheimers Dement (2015) 11(6):60821.e7
About 38% are motivated by cost savings through dose stretching
If someone has type 2 diabetes and/or obesity, however, their naturally occurring GLP-1 may not be as robust
Key points GLP-1 is a hormone that increases insulin release and prevents the release of too much glucagon, helping manage blood glucose levels in individuals with type 2 diabetes GLP-1 receptor agonists, such as liraglutide and semaglutide, effectively reduce blood glucose levels Semaglutide is more effective than liraglutide at reducing blood sugar levels Tirzepatide is a newer GLP-1 receptor agonist that also mimics the actions of another hormone called GIP, which can also reduce blood sugar levels A randomised controlled trial showed that tirzepatide led to more significant blood sugar reductions than semaglutide across three doses Tirzepatide may be more effective than semaglutide at higher doses, but this needs further investigation Liraglutide and semaglutide are available in the UK and the US, while tirzepatide is only available in the US but is likely to be approved in the UK soon
By the time Knudsen returned from maternity leave in 1994, all of her former colleagues had left and the future of the GLP-1 project looked bleak
I got three texts within an hour: Does this mean we wont need the research suppliers anymore? Can we go back to real pharmacies? Dr
.png.jpg)
